News and events

This book provides original insights into how “new biology” and “translational” policies to drive a health bioeconomy are reshaping innovation ecosystems, and disrupting R&D practices, institutional and professional boundaries, and notions of “value” in healthcare.

At the EMBO/EMBL Science and Society Conference Joyce Tait talked about ’Who needs biotechnology, who wants it and who are the stakeholders?‘

Among the Innogen researchers traveling to Rwanda to attend and present at the conference, Geoff Banda will talk about drug development in Africa.

Joyce talks about ‘Risk regulation, uncertainty and ethics in governing biotechnologies’ on the 10th of November 2015.

Professor Joanna Chataway moderated the Technology, Economic Growth, Distribution and Stability session.

There were three presentations by OU DPP/Innogen Institute researchers in a panel on Health Delivery Innovation.

Farah talked about ‘A history of the Hepatitis B vaccine’

In the edition of Good Morning Scotland of the 3rd of October, Joyce called for a rational debate about genetically modified crops, following the ban on GM crops by the Scottish Government.

Geoff’s talk was about ‘Regenerative medicine business models: towards an indicative model and typologies’

Joanna Chataway (Vice-President of Globelics), David Wield and Theo Papaioannou will be among the Innogen members attending and presenting papers at this conference.